Salivary DJ-1 could be an indicator of parkinson's disease progression

Frontiers in Aging Neuroscience

Volumn 6, Issue JUN, 2014, Pages

  Kang, Wen Yan ^a   Yang, Qiong ^a   Jiang, Xu Feng ^a   Chen, Wei ^a   Zhang, Lin Yuan ^a   Wang, Xiao Ying ^a   Zhang, Li Na ^b   Quinn, Thomas J ^c   Liu, Jun ^a   Chen, Sheng Di ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Asaliva; Dj 1; Dopamine transporter; Parkinson's disease; Spect

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; CARBIDOPA PLUS LEVODOPA; DJ 1 PROTEIN; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; MONOAMINE OXIDASE B INHIBITOR; SALIVA PROTEIN; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M;

ADULT; AGE; AKINETIC RIGID DOMINANT TYPE; ARTICLE; CAUDATE NUCLEUS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DENSITY; DISEASE ASSOCIATION; DISEASE COURSE; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PROGNOSIS; PUTAMEN; QUANTITATIVE ANALYSIS; SALIVA LEVEL; SEX RATIO; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREMOR DOMINANT TYPE; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 84904564452     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00102     Document Type: Article

References (26)

1. Bonne, N. J., and Wong, D. T. (2012). Salivary biomarker development using genomic, proteomic and metabolomic approaches. Genome Med. 4, 82. doi: 10.1186/gm383
2. Devic, I., Hwang, H., Edgar, J. S., Izutsu, K., Presland, R., Pan, C., et al. (2011). Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain 134, e178. doi: 10.1093/brain/awr015
3. Eggers, C., Kahraman, D., Fink, G. R., Schmidt, M., and Timmermann, L. (2011). Akinetic-rigid and tremor-dominant Parkinson's disease patients show different patterns of FP-CIT single photon emission computed tomography. Mov. Disord. 26, 416-423. doi: 10.1002/mds.23468
4. Haas, B. R., Stewart, T. H., and Zhang, J. (2012). Premotor biomarkers for Parkinson's disease - a promising direction of research. Transl. Neurodegener. 1, 11. doi: 10.1186/2047-9158-1-11
5. Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., et al. (2010). DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133, 713-726. doi: 10.1093/brain/awq008
6. Hughes, A. J., Ben-Shlomo, Y., Daniel, S. E., and Lees, A. J. (1992). What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 57, S34-S38. doi: 10.1212/WNL.42.6.1142
7. Hwang, W. J., Yao, W. J., Wey, S. P., and Ting, G. (2004). Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease. J. Nucl. Med. 45, 207-213.
8. Jankovic, J. (2008). Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 79, 368-376. doi: 10.1136/jnnp.2007.131045
9. Kumru, H., Santamaria, J., Tolosa, E., and Iranzo, A. (2007). Relation between subtype of Parkinson's disease and REM sleep behavior disorder. Sleep Med. 8, 779-783. doi: 10.1016/j.sleep.2007.02.005
10. Kung, M. P., Stevenson, D. A., Plossl, K., Meegalla, S. K., Beckwith, A., Essman, W. D., et al. (1997). [99mTc]TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent. Eur. J. Nucl. Med. 24, 372-380. doi: 10.1007/BF00881808
11. Maita, C., Tsuji, S., Yabe, I., Hamada, S., Ogata, A., Maita, H., et al. (2008). Secretion of DJ-1 into the serum of patients with Parkinson's disease. Neurosci. Lett. 431, 86-89. doi: 10.1016/j.neulet.2007.11.027
12. Marek, K., Innis, R., van Dyck, C., Fussell, B., Early, M., Eberly, S., et al. (2001). [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57, 2089-2094. doi: 10.1212/WNL.57.11.2089
13. Mollenhauer, B., Trenkwalder, C., von Ahsen, N., Bibl, M., Steinacker, P., Brechlin, P., et al. (2006). Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement. Geriatr. Cogn. Disord. 22, 200-208. doi: 10.1159/000094871
14. Romenets, S. R., Gagnon, J. F., Latreille, V., Panniset, M., Chouinard, S., Montplaisir, J., et al. (2012). Rapid eye movement sleep behavior disorder and subtypes of Parkinson's disease. Mov. Disord. 27, 996-1003. doi: 10.1002/mds.25086
15. Sherer, T. B. (2011). Biomarkers for Parkinson's disease. Sci. Transl. Med. 3, 79ps14. doi: 10.1126/scitranslmed.3002488
16. Shi, M., Furay, A. R., Sossi, V., Aasly, J. O., Armaly, J., Wang, Y., et al. (2012). DJ-1 and alphaSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiol. Aging 33, 836.e835-837. doi: 10.1016/j.neurobiolaging.2011.09.015
17. Shih, M. C., Franco de Andrade, L. A., Amaro, E. Jr. Felicio, A. C., Ferraz, H. B., Wagner, J., et al. (2007). Higher nigrostriatal dopamine neuron loss in early than late onset Parkinson's disease?-a [99mTc]-TRODAT-1 SPECT study. Mov. Disord. 22, 863-866. doi: 10.1002/mds.21315
18. Stewart, T., Sui, Y. T., Gonzalez-Cuyar, L. F., Wong, D. T., Akin, D. M., Tumas, V., et al. (2014). Cheek cell-derived alpha-synuclein and DJ-1 do not differentiate Parkinson's disease from control. Neurobiol. Aging 35, 418-420. doi: 10.1016/j.neurobiolaging.2013.08.008
19. Stoessl, A. J. (2012). Neuroimaging in the early diagnosis of neurodegenerative disease. Transl. Neurodegener. 1, 5. doi: 10.1186/2047-9158-1-5
20. Wang, Z., Liu, J., Chen, S., Wang, Y., Cao, L., Zhang, Y., et al. (2011). DJ-1 modulates the expression of Cu/Zn-superoxide dismutase-1 through the Erk1/2-Elk1 pathway in neuroprotection. Ann. Neurol. 70, 591-599. doi: 10.1002/ana.22514
21. Waragai, M., Nakai, M., Wei, J., Fujita, M., Mizuno, H., Ho, G., et al. (2007). Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease. Neurosci. Lett. 425, 18-22. doi: 10.1016/j.neulet.2007.08.010
22. Waragai, M., Sekiyama, K., Sekigawa, A., Takamatsu, Y., Fujita, M., and Hashimoto, M. (2010). Alpha-Synuclein and DJ-1 as Potential Biological Fluid Biomarkers for Parkinson's Disease. Int. J. Mol. Sci. 11, 4257-4266. doi: 10.3390/ijms11114257
23. Waragai, M., Wei, J., Fujita, M., Nakai, M., Ho, G. J., Masliah, E., et al. (2006). Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem. Biophys. Res. Commun. 345, 967-972. doi: 10.1016/j.bbrc.2006.05.011
24. Winkler-Stuck, K., Kirches, E., Mawrin, C., Dietzmann, K., Lins, H., Wallesch, C. W., et al. (2005). Re-evaluation of the dysfunction of mitochondrial respiratory chain in skeletal muscle of patients with Parkinson's disease. J. Neural. Transm. 112, 499-518. doi: 10.1007/s00702-004-0195-y
25. Wright Willis, A., Evanoff, B. A., Lian, M., Criswell, S. R., and Racette, B. A. (2010). Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology 34, 143-151. doi: 10.1159/000275491
26. Zhang, A., Sun, H., and Wang, X. (2012). Saliva metabolomics opens door to biomarker discovery, disease diagnosis, and treatment. Appl. Biochem. Biotechnol. 168, 1718-1727. doi: 10.1007/s12010-012-9891-5